1. Home
  2. Medical News
  3. Pulmonary Medicine
advertisement

Tezepelumab Alters Airway-Cell Gene Expression in Asthma

Illustrated bronchial airway epithelium and smooth muscle layer showing cellular signaling in uncontrolled asthma
11/06/2026

Key Takeaways

  • In unstimulated bronchial epithelial cells, the after-to-before changes in S100A8 and S100A9 mRNA were significantly lower with tezepelumab than with placebo.
  • Virus-mimic-associated transcriptional changes suggested inflammatory pathway shifts, but selected NF-κB readouts showed no significant overall between-group differences on validation.
  • Selected NF-κB responses differed in an exploratory higher-inflammation subgroup, without establishing a patient-selection marker.
  • Tezepelumab-group epithelial conditioned medium induced less TGF-β2 mRNA in cultured bronchial smooth-muscle cells than placebo-group medium.
In uncontrolled asthma, airway epithelial cells respond to viral triggers and send signals to underlying smooth muscle. Blocking the epithelial-derived cytokine thymic stromal lymphopoietin (TSLP) raises a cellular question: how might that intervention change inflammatory signaling and communication between these airway cell types?

Investigators collected bronchial epithelial cells before and after 12 weeks of tezepelumab or placebo in the randomized, double-blind, placebo-controlled phase 2 UPSTREAM study. Samples from the Copenhagen-associated Danish trial were used for mechanistic experiments, not a new clinical-endpoint trial. Wider validation and conditioned-medium experiments involved 13 epithelial donors per arm; exploratory NanoString profiling involved nine tezepelumab donors and two placebo donors. Investigators grew cells as submerged cultures and exposed them to polyinosinic:polycytidylic acid (poly(I:C)), a synthetic viral double-stranded RNA mimic rather than a live virus. They used gene profiling, reverse transcription quantitative polymerase chain reaction (RT-qPCR), secretion assays, and separate recombinant-TSLP experiments. Stimulated epithelial conditioned medium was also transferred to cultured bronchial smooth-muscle cells from one healthy control.

In unstimulated epithelial cells, only S100A8 and S100A9 met the exploratory differential-expression threshold of false discovery rate (FDR) <0.1. Full-cohort RT-qPCR showed significantly lower after-to-before changes in messenger RNA (mRNA) expression for both genes with tezepelumab than with placebo. Stimulated mRNA comparisons and secreted S100A8/S100A9 protein showed no significant between-group differences. After poly(I:C) exposure, 63 of 594 assayed genes met the exploratory threshold, predominantly with lower expression, and tumor necrosis factor alpha (TNF-α)/nuclear factor kappa B (NF-κB) signaling was enriched. Selected full-cohort comparisons of TNFSF15, TRAF1, and phosphorylated p65 showed no significant overall treatment differences.

In separate gain-of-function experiments, added recombinant TSLP increased poly(I:C)-associated S100A8, S100A9, TNFSF15, and TRAF1 transcription and NF-κB activation. Small post hoc higher-inflammation groups showed differential selected phosphorylated p65 and inhibitor of nuclear factor kappa B alpha (IκBα) responses, without establishing a predictive biomarker. Conditioned medium from stimulated epithelium collected after tezepelumab induced lower transforming growth factor beta 2 (TGF-β2) mRNA in smooth-muscle cells than placebo-group medium. Vascular endothelial growth factor A (VEGFA) mRNA showed only a downward trend.

The imbalanced exploratory profiling comparison, small overlapping post hoc subgroups, variable responses, and absent significant overall NF-κB confirmation limit interpretation of the pathway and subgroup patterns. Submerged epithelial monolayers and a synthetic viral mimic do not reproduce differentiated airway tissue or infection with a replicating virus. The downstream experiments used smooth-muscle cells from one healthy control and measured transcription, not proliferation, migration, airway remodeling in vivo, or clinical improvement. Recombinant TSLP responses therefore do not establish a mechanism for tezepelumab’s clinical effects.

The authors hypothesized that TSLP blockade is associated with altered epithelial inflammatory transcription and changed smooth-muscle transcription in response to epithelial conditioned medium in uncontrolled asthma. The observed ex-vivo cellular responses do not establish structural airway changes or clinical effects in vivo.

Clinician Questions

Before tezepelumab treatment, how did epithelial conditioned medium affect VEGFA and TGF-β2 expression in bronchial smooth-muscle cells?

Before tezepelumab or placebo treatment, conditioned medium from bronchial epithelial cells of patients with uncontrolled asthma increased VEGFA mRNA in cultured bronchial smooth-muscle cells whether the epithelium was unstimulated or exposed to the poly(I:C) viral mimic. TGF-β2 mRNA increased significantly only with medium from poly(I:C)-stimulated epithelium.

Did baseline inflammatory status change TSLP and IL-33 responses after tezepelumab in uncontrolled asthma?

In exploratory post hoc groups of tezepelumab-treated patients with uncontrolled asthma, epithelial TSLP mRNA after poly(I:C) stimulation fell in the higher-inflammation cluster but rose in the lower-inflammation cluster. The between-cluster comparison for IL-33 mRNA was not significant; these clusters were not validated treatment-response biomarkers.

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free